Clinical trial · no report yet · Phase 3
SUCCESSOR-2
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
- NCT05552976 ↗
- Active not recruiting
- Bristol-Myers Squibb
- 104 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 51 | |
| X threads | 35 | |
| Podcasts | 15 | |
| X videos | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Mezigdomide; Carfilzomib; Dexamethasone
- Arms
- MeziKd (Mezigdomide + Carfilzomib + Dexamethasone) · Experimental
- Kd (Carfilzomib + Dexamethasone) · Active comparator
- Enrollment
- 606
- Primary outcomes
- Progression-free Survival (PFS)
- Sponsor
- Bristol-Myers Squibb
- Start
- Jan 10, 2023
- Primary completion
- Sep 28, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05552976 · updated Sep 24, 2026
Publications
linked from the registry- Dimopoulos MA, Schjesvold F, Fu C, Hartley-Brown MA, Gomez C, Reece D, Mikala G, Alkharabsheh O, Parrish C, de Queiroz Crusoe E, Galvez K, Idrobo H, White D, Gupta R, Lee C, Liu CJ, Quach H, Wang Y, Cerchione C, Forsyth C, Hungria V, Kalaskar P, Graklanov V, Ho PJ, Klaiber-Hakimi M, Kwong YL, Louzada M, Mazumder A, Miles O, Nagarajan C, Prasad SVSS, Raab MS, Varga G, von der Heyde E, Xia Z, Ochoa PA, Oriol A, Yuda J, Kuroda J, Gong J, Zhou Z, Maciag P, Yu B, Rocci A, Koo P, Katz J, Richardson PG; SUCCESSOR-2 Trial Investigators. Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial. Lancet. 2026 Jul 18;408(10551):219-233. doi: 10.1016/S0140-6736(26)01088-3. Epub 2026 Jun 14. PubMed 42289183